La chaîne d'options affiche les données clés des options sur actions de Mainz Biomed à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Mainz Biomed..

Mainz Biomed (NASDAQ:MYNZ) Stock, Chaîne d'Options

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV

<ul>
<li>Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options</li>
<li>Phase II data show potential of efimosfermin to reverse liver fibrosis, demonstrated in metabolic dysfunction-associated steatohepatitis (a form of SLD)</li>
<li>Unique properties offer potential for efimosfermin to be a new standard-of-care</li>
<li>Significantly expands GSK's hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential first launch in 2029</li>
</ul>

Macro Economic Events

News

Econ #s

Economics

INDA

India Wholesale Price Index (WPI) Inflation (YoY) For April 0.85% Vs. 1.76% Est.; 2.05% Prior

<ul>
<li>Marks FirstCash's strategic entry into the UK market through an established, industry-leading brand;</li>
<li>Provides further geographic diversification and unlocks additional growth opportunities;</li>
<li>Expected to be meaningfully accretive to EBITDA and EPS;</li>
<li>Strengthens FirstCash's position as a global leader in pawn operations</li>
</ul>

FCFS

FirstCash To Acquire H&T Group For $394M In UK Expansion Deal Expected To Deliver Meaningful EBITDA And EPS Accretion

GSK To Expand Liver Disease Portfolio With $1.2B Acquisition Of Boston Pharmaceuticals' Efimosfermin, Targeting 2029 Launch

Dynatrace, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) will release earnings results for the fourth quarter, before the opening bell on <a href="https://www.benzinga.com/quote/DT/earnings">Wednesday, May 14.</a>
Analysts expect the Waltham, Massachusetts-based company to report quarterly earnings at 30 cents per share, compared to 30 cents per share in the year-ago period. Dynatrace projects to report quarterly revenue at $435.14 million, compared to $380.85 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 22, Dynatrace announced that Steve McMahon will join Dynatrace as its new Chief Customer Officer.
Dynatrace shares gained 0.1% to close at $50.54 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/DT/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Rosenblatt analyst Blair Abernethy maintained a Buy rating with a price target of $67 on May 13, 2025. This analyst has an accuracy rate of 70%.</li>
<li>UBS analyst Karl Keirstead maintained a Neutral rating and slashed the price target from $62 to $50 on April 30, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Loop Capital analyst Yun Kim maintained a Hold rating and cut the price target from $55 to $44 on April 23, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Barclays analyst Raimo Lenschow maintained an Overweight rating and lowered the price target from $67 to $55 on April 21, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Jefferies analyst Brent Thill maintained a Buy rating and cut the price target from $65 to $60 on April 7, 2025. This analyst has an accuracy rate of 77%.</li>
</ul>
Considering buying DT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14022507/image-149-1024x583.png" alt="" class="wp-image-914449" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14022507/image-149-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14022507/image-149-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14022507/image-149-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14022507/image-149.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Dynatrace Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Valeura Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VLE#TSX">VLE</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.26 by 50 percent. This is a 27.78 percent decrease over earnings of $0.18 per share from the same period last year. The company reported $148.08 million in sales this quarter. This is a 0.89 percent decrease over sales of $149.41 million the same period last year.

Earnings Misses

TSX:VLE

VLERF

Valeura Energy Q1 EPS $0.13 Misses $0.26 Estimate, Sales $148.08M Down From $149.41M YoY

Tech analyst Dan Ives offers a candid assessment of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) as demand pressures mount and investor attention shifts toward its autonomy and AI roadmap.
What Happened: Appearing on the Risk Reversal podcast on Tuesday, Ives flagged Tesla&#8217;s worsening sales trends in Europe, estimating &#8220;15% to 20% permanent demand destruction,&#8221; up from his prior forecast of 5%.
&#8220;There&#8217;s some heavy lifting ahead,&#8221; Ives says, citing rising competitive pressures from the likes of Chinese auto giant BYD Co Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>), both across China and Europe. 
With its core EV growth under pressure, Ives argues the company&#8217;s future increasingly relies on its autonomy and AI initiatives, while describing the next 6 to 8 months as a pivotal stretch. &#8220;You need to show that this is going to ultimately kick off the autonomous vision,&#8221; he says, pointing to the upcoming launch of the &#8220;CyberCab&#8221; as a potential inflection point.
See Also: <a href="https://www.benzinga.com/25/05/45381782/elon-musk-vows-to-spend-less-time-in-white-house-doge-office-investors-warn-the-damage-is-done-and-teslas-troubles-are-far-from-over">Tesla Supplier CATL Sets Modest Underwriting Fees For World&#8217;s Biggest IPO Of 2025</a>
Speaking on Elon Musk&#8217;s artificial intelligence startup, xAI that now owns X (formerly known as Twitter), Ives believes that such a move could help justify Tesla&#8217;s premium valuations by embedding advanced AI capabilities directly into its stack. 
Ives sees the odds of a Tesla-xAI merger at 35%, &#8220;The chance that that happens in the next 6 to 9 months is not 5%, it's more like 35%,&#8221; he says.
Why It Matters: Tesla's struggles in Europe <a href="https://benzinga.com/markets/25/05/45192200/teslas-european-woes-deepen-as-new-car-sales-for-april-plunge-in-spain-as-chinese-rivals-soar">deepened in recent weeks</a>, with new car sales in Spain falling 36% year-over-year in April, even as Chinese competitors posted a 54% increase over the same period.
The company nonetheless rejoined the trillion-dollar club on Tuesday, following a 40% rally from its April lows. In addition to the easing of trade tensions between the U.S. and China, the promised <a href="https://www.benzinga.com/news/25/05/45387469/tesla-stock-soars-amid-china-tariff-relief-and-robotaxi-buzz">debut of robotaxis</a> in Austin next month has led to this momentum.
Ives has always been bullish on <a href="https://benzinga.com/25/05/45126638/tesla-will-own-the-autonomous-market-dan-ives-says-shrugging-off-waymo-toyota-agreement">Tesla&#8217;s autonomous plays</a>, stating recently that the company &#8220;will own the autonomous market,&#8221; since &#8220;no one can compete with their scale and scope.&#8221; 
Others, including fund manager Gary Black, have similar views. Black said he <a href="https://benzinga.com/25/05/45339797/gary-black-doubles-down-on-ubers-autonomy-upside-reflects-on-tesla-debates-i-was-right-on-volume-pr-and-robotaxis">remains bullish on Tesla</a> over the long term, stating that &#8220;as EV adoption and demand for autonomy increase, $TSLA remains the best positioned to capitalize on these two megatrends.&#8221;
Price Action: Tesla shares rose 4.93% to $334.07 on Tuesday and gained nearly 0.7% in after-hours trading.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Why Dan Ives Says Palantir Is the Real AI Winner Despite Sky-High Valuation" width="500" height="281" src="https://www.youtube.com/embed/JkcotyLg3oI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="136" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM-1024x136.png" alt="" class="wp-image-914425" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM-1024x136.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM-768x102.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM-1536x205.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14020320/Screenshot-2025-05-14-at-11.33.05-AM.png 1606w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
For more insights on Tesla&#8217;s stock score and price trends, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a>. 
Photo courtesy: Kemarrravv13 on Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45381782/elon-musk-vows-to-spend-less-time-in-white-house-doge-office-investors-warn-the-damage-is-done-and-teslas-troubles-are-far-from-over">Elon Musk Vows To Spend &#8216;Less Time&#8217; In White House DOGE Office – Investors Warn &#8216;The Damage Is Done&#8217; And Tesla&#8217;s Troubles Are &#8216;Far From Over&#8217;</a></li>
</ul>

BYDDF

TSLA

Dan Ives Says Tesla's Future Hinges On Autonomy As Europe Demand Craters—xAI Acquisition Could Be Musk's Next Big Bet: 'Heavy Lifting Ahead'

The estimated impact from the series of changes in U.S. tariff policy at this time is reflected in the above forecasts for operating income, income before income taxes and net income attributable to Sony Group Corporation's stockholders. The estimated impact is calculated based on the assumptions that the reciprocal tariff rates announced on April 2, 2025 will be applied after the end of the temporary suspension announced on April 9, and that other tariffs will remain unchanged from the end of April. The impact of the partial removal and temporary suspension of the additional and reciprocal tariffs on China by the U.S. announced on May 12 is not included in the assumptions used for estimating the relevant impact. The actual impact could vary significantly from this estimation if future tariff policy or other factors are changed.

Guidance

Sony Group Corporation American Depositary Shares

SONY

Sony's Forecast Factors In U.S. Tariffs As Of April But Excludes The May 12 China Tariff Changes; The Company Noted The Actual Impact May Vary With Future Policy Shifts

President Donald Trump singled out Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang for praise during a U.S.-Saudi Investment Forum on Tuesday, highlighting the chipmaker&#8217;s planned $500 billion <a href="https://www.benzinga.com/markets/25/05/45397196/jensen-huangs-wealth-surges-37-since-liberation-day-lows-as-nvidia-re-enters-3-trillion-market-cap-club-on-saudi-chip-pact">investment in U.S. artificial intelligence infrastructure</a>.
What Happened: &#8220;I see my friend is here, Jensen. [Apple Inc. CEO] Tim Cook isn&#8217;t here, but you are,&#8221; Trump said at the Saudi summit. &#8220;What a job you&#8217;ve done. He&#8217;s got 99% of the chip market. That&#8217;s not easy to beat.&#8221;
Trump&#8217;s comments came as part of a broader announcement of over $1 trillion in investments flowing into the United States. The president specifically acknowledged Huang&#8217;s commitment to building AI infrastructure in America over the next four years.
&#8220;Thank you for the investment. We are proud to have you in our country,&#8221; Trump told Huang, who was present at the forum.
The praise follows Nvidia&#8217;s <a href="https://www.benzinga.com/25/04/44799936/nvidia-to-build-500b-ai-infrastructure-in-us-in-the-next-four-years-details">April announcement of plans to partner with manufacturers</a> including Foxconn, Wistron, TSMC, Amkor, and SPIL to establish production centers in Arizona and Texas. Production of Nvidia&#8217;s Blackwell chips is already underway at TSMC&#8217;s Phoenix facility.
See Also: <a href="https://www.benzinga.com/markets/bonds/25/05/45396490/peter-schiff-says-trade-truce-aside-the-world-is-losing-confidence-in-dollar-and-in-us-ability-to-put-fiscal-house-in-order">Peter Schiff Says Trade Truce Aside, The World Is &#8216;Losing Confidence&#8217; In Dollar And In US Ability To Put &#8216;Fiscal House In Order&#8217;</a>
Why It Matters: The comments coincide with Nvidia&#8217;s stock rally, which has driven the company <a href="https://www.benzinga.com/markets/25/05/45397196/jensen-huangs-wealth-surges-37-since-liberation-day-lows-as-nvidia-re-enters-3-trillion-market-cap-club-on-saudi-chip-pact">back into the $3 trillion market cap club</a>. Shares surged following Monday&#8217;s de-escalation in U.S.-China trade tensions and Tuesday&#8217;s announcement of a deal to supply 18,000 GB300 Blackwell chips to Saudi-based AI startup Humain.
Huang, whose <a href="https://www.benzinga.com/markets/25/05/45397196/jensen-huangs-wealth-surges-37-since-liberation-day-lows-as-nvidia-re-enters-3-trillion-market-cap-club-on-saudi-chip-pact">net worth stood at approximately $114 billion on Tuesday</a>, has seen his fortune increase 37% since early April lows following the &#8220;Liberation Day&#8221; tariffs announcement.
The Nvidia investment was mentioned alongside other major U.S. commitments, including Apple Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) $500 billion investment and Taiwan Semiconductor Manufacturing Company&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) $200 billion investment.
Photo Courtesy: jamesonwu1972 on Shutterstock.com
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45396297/cathie-wood-dumps-palantir-as-stock-touches-peak-prices-bails-on-soaring-flying-taxi-maker-archer-aviation">Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

AAPL

NVDA

Trump Praises Nvidia CEO Jensen Huang At Saudi Summit: 'Tim Cook Isn't Here, But You Are' Controlling 99% Of The Chip Market: 'That's Not Easy To Beat'

Sony's Forecast For Fiscal Year Ending March 31, 2026: Expects Sales From Continuing Operations Of ¥11.7T (-2.9% YoY), Operating Income Of ¥1.28T (+0.3% YoY), And Net Income Of ¥930B (-12.9% YoY)

Sony Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.12 by 78.33 percent. This is a 1.9 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $17.25 billion which missed the analyst consensus estimate of $20.40 billion by 15.46 percent. This is a 26.48 percent decrease over sales of $23.46 billion the same period last year.

Earnings Beats

Sony Group Q4 EPS $0.21 Beats $0.12 Estimate, Sales $17.25B Miss $20.40B Estimate

Germany Consumer Price Index (MoM) For April 0.4% Vs. 0.4% Est.; 0.3% Prior

Germany Consumer Price Index (YoY) For April 2.1% Vs. 2.1% Est.; 2.2% Prior

Sony Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported quarterly earnings of ¥187.92 per share which beat the analyst consensus estimate of ¥180.09 by 4.35 percent. This is a 19.59 percent increase over earnings of ¥157.14 per share from the same period last year. The company reported quarterly sales of ¥12.957 trillion which missed the analyst consensus estimate of ¥13.336 trillion by 2.84 percent. This is a 0.48 percent decrease over sales of ¥13.020 trillion the same period last year.

Sony Group FY 2024 GAAP EPS ¥187.92 Beats ¥180.09 Estimate, Sales ¥12.957T Miss ¥13.336T Estimate

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) will release its third-quarter financial results after the closing <a href="https://www.benzinga.com/quote/CSCO/earnings">bell on Wednesday, May 14.</a>
Analysts expect the San Jose, California-based company to report quarterly earnings at 92 cents per share, up from 88 cents per share in the year-ago period. Cisco projects quarterly revenue of $14.06 billion, compared to $12.7 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 28, Evercore ISI Group analyst Amit Daryanani maintained Cisco with an Outperform rating and lowered the price target from $75 to $67.
The recent buzz around Cisco may have investors eyeing potential gains from the company's dividends. Currently, Cisco offers an annual dividend yield of 2.66%. That&#8217;s a quarterly dividend of 41 cents per share ($1.64 a year).
To figure out how to earn $500 monthly from Cisco, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Cisco's $1.64 dividend: $6,000 / $1.64 = 3,659 shares.
So, an investor would need to own approximately $225,651 worth of Cisco, or 3,659 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.64 = 732 shares, or $45,142 to generate a monthly dividend income of $100.
Investors should note that dividend yields can change on a rolling basis. The dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
CSCO Price Action: Shares of Cisco gained by 3.2% to close at $61.67 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45347009/top-2-tech-stocks-that-may-crash-in-q2">Top 2 Tech Stocks That May Crash In Q2</a></li>
</ul>
Image: Shutterstock

Long Ideas

CSCO

How To Earn $500 A Month From Cisco Stock Ahead Of Q3 Earnings

Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) reported quarterly losses of $(3.37) per share. This is a 99.15 percent increase over losses of $(394.76) per share from the same period last year.

BJDX

Bluejay Diagnostics Q1 EPS $(3.37) Up From $(394.76) YoY

Investcorp Credit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICMB#NASDAQ">ICMB</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.11 by 54.55 percent. This is a 64.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $4.37 million which missed the analyst consensus estimate of $5.27 million by 17.13 percent. This is a 34.00 percent decrease over sales of $6.62 million the same period last year.

ICMB

Investcorp Credit Q3 EPS $0.05 Misses $0.11 Estimate, Sales $4.37M Miss $5.27M Estimate

Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.35) by 28.57 percent. This is a 36.36 percent decrease over losses of $(0.33) per share from the same period last year.

BLTE

Belite Bio Q1 EPS $(0.45) Misses $(0.35) Estimate

Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.31) by 938.71 percent. This is a 84.09 percent increase over losses of $(20.24) per share from the same period last year. The company reported $2.57 million in sales this quarter. This is a 20.33 percent increase over sales of $2.13 million the same period last year.

TVRD

Tvardi Therapeutics Q1 EPS $(3.22) Misses $(0.31) Estimate, Sales $2.57M Up From $2.13M YoY

Reported Earlier, GreenPower Motor Announces $2M Term Loan Offering To Support Production And Working Capital

Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) reported quarterly losses of $(2.75) per share. This is a 49.45 percent increase over losses of $(5.44) per share from the same period last year.

PTIX

Protagenic Therapeutics Q1 EPS $(2.75) Up From $(5.44) YoY

Health Care

Press Releases

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

General

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed Expands into Switzerland with labor team w

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

MYNZ

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GT Biopharma

HCW Biologics

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Oragenics

PharmaCyte Biotech

Sunshine Biopharma

SILO Pharma

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Turnstone Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Maxim Group

JonesTrading

Screenshot 2025-04-15 at 7.03.21 PM

Biotech

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2025-04-02 at 9.29.30 PM

Mainz BioMed&#39;s Trial To Bring Critical Early Cancer Detection One Step Closer

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Mainz Biomed

Mainz Biomed (MYNZ) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL